圣达生物
(603079)
| 流通市值：22.03亿 | | | 总市值：22.03亿 |
| 流通股本：1.71亿 | | | 总股本：1.71亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 271,800,830.11 | 323,722,320.84 | 326,016,344.18 | 310,474,017.39 |
| 应收票据及应收账款 | 128,767,574.62 | 118,145,823.72 | 132,330,947.59 | 136,917,191.32 |
| 其中：应收票据 | 2,879,273.3 | 1,215,026.25 | 822,557.5 | 715,373.75 |
| 应收账款 | 125,888,301.32 | 116,930,797.47 | 131,508,390.09 | 136,201,817.57 |
| 应收款项融资 | 2,241,592.11 | 1,112,435.57 | 1,814,700 | 3,211,379.93 |
| 预付款项 | 4,380,630 | 2,810,031.48 | 6,284,211.21 | 4,410,843.56 |
| 其他应收款合计 | 652,660.77 | 599,320.02 | 1,499,989.6 | 1,319,958.69 |
| 其中:应收利息 | - | - | - | 742,194.44 |
| 存货 | 238,910,554.47 | 228,482,255.95 | 254,253,416.01 | 272,729,652.15 |
| 一年内到期的非流动资产 | - | - | 10,000,000 | 10,000,000 |
| 其他流动资产 | 16,856,042.84 | 17,262,846.66 | 9,881,522.23 | 4,033,776.8 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 676,623,402.84 | 695,148,552.16 | 745,109,973.56 | 748,114,342.58 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 10,700,000 | 10,700,000 | 10,700,000 | 10,700,000 |
| 固定资产 | 422,415,686.84 | 427,038,182.01 | 438,821,114.37 | 453,674,675.77 |
| 在建工程 | 272,352,329.92 | 247,315,674.72 | 202,203,110.19 | 165,750,741.06 |
| 使用权资产 | 417,491.53 | 417,491.53 | 556,655.36 | 695,819.18 |
| 无形资产 | 230,100,779.81 | 231,815,599.9 | 225,018,964.45 | 218,018,221.21 |
| 商誉 | 10,909,393.98 | 10,909,393.98 | 10,909,393.98 | 10,909,393.98 |
| 长期待摊费用 | 11,976,316.77 | 8,670,991.1 | 7,472,251.7 | 5,456,276 |
| 递延所得税资产 | 759,751.4 | 889,251.68 | 2,418,065.75 | 2,433,861.82 |
| 其他非流动资产 | 118,935,596.13 | 86,280,420.8 | 57,090,830.78 | 38,731,410.78 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,078,567,346.38 | 1,024,037,005.72 | 955,190,386.58 | 906,370,399.8 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,755,190,749.22 | 1,719,185,557.88 | 1,700,300,360.14 | 1,654,484,742.38 |
| 流动负债: | | | | |
| 短期借款 | 111,975,777.76 | 93,993,881.93 | 68,064,305.55 | 60,057,083.33 |
| 应付票据及应付账款 | 159,871,166.25 | 144,354,689.27 | 130,984,071.56 | 138,591,495.39 |
| 其中：应付票据 | 84,859,499.11 | 76,769,707.21 | 73,095,206.09 | 79,054,171.29 |
| 应付账款 | 75,011,667.14 | 67,584,982.06 | 57,888,865.47 | 59,537,324.1 |
| 合同负债 | 6,504,964.58 | 2,923,295.97 | 3,733,126.78 | 4,525,792.8 |
| 应付职工薪酬 | 12,047,557.12 | 26,080,176.08 | 20,398,365.54 | 16,514,189.6 |
| 应交税费 | 4,170,437.6 | 10,999,973.87 | 8,442,925.09 | 8,037,105.05 |
| 其他应付款合计 | 14,105,087.86 | 16,368,389.02 | 20,582,542.38 | 22,402,087.17 |
| 一年内到期的非流动负债 | 304,323.57 | 447,323.57 | 304,323.56 | 304,323.56 |
| 其他流动负债 | 385,713.07 | 286,613.47 | 270,256 | 314,641.84 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 309,365,027.81 | 295,454,343.18 | 252,779,916.46 | 250,746,718.74 |
| 非流动负债: | | | | |
| 长期借款 | 173,000,000 | 144,000,000 | 110,099,305.56 | 67,060,486.11 |
| 租赁负债 | - | - | 306,721.64 | 224,799.66 |
| 递延收益 | 6,106,071.02 | 5,464,423.38 | 5,640,863.54 | 6,653,639.85 |
| 递延所得税负债 | 4,540,110.41 | 4,276,770.45 | 7,343,801.6 | 7,741,700.05 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 183,646,181.43 | 153,741,193.83 | 123,390,692.34 | 81,680,625.67 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 493,011,209.24 | 449,195,537.01 | 376,170,608.8 | 332,427,344.41 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 171,188,958 | 171,188,958 | 171,188,958 | 171,188,958 |
| 资本公积 | 669,194,129.65 | 669,194,129.65 | 669,194,129.65 | 669,194,129.65 |
| 减:库存股 | 22,080,656.17 | 8,966,294.26 | 6,417,824.53 | 5,067,032.04 |
| 盈余公积 | 57,259,119.57 | 57,259,119.57 | 57,259,119.57 | 57,259,119.57 |
| 未分配利润 | 369,817,659.63 | 366,004,598.91 | 416,395,998.46 | 413,750,802.73 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,245,379,210.68 | 1,254,680,511.87 | 1,307,620,381.15 | 1,306,325,977.91 |
| 少数股东权益 | 16,800,329.3 | 15,309,509 | 16,509,370.19 | 15,731,420.06 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,262,179,539.98 | 1,269,990,020.87 | 1,324,129,751.34 | 1,322,057,397.97 |
| 负债和股东权益合计 | 1,755,190,749.22 | 1,719,185,557.88 | 1,700,300,360.14 | 1,654,484,742.38 |
| 公告日期 | 2024-04-20 | 2024-04-20 | 2023-10-28 | 2023-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |